Interesting read, but the article deserves a harder look than it usually gets when it circulates.
The parts grounded in real pharmacology. Glargine is designed for a relatively flat, prolonged release profile with no pronounced peak, which is exactly why it was developed as a basal insulin for clinical use. The claim that low exogenous insulin just replaces endogenous output is also consistent with how the pancreas works. Beta cells secrete to defend a glucose range, so extra circulating insulin suppresses endogenous secretion. And the statement that insulin and growth hormone both worsen insulin sensitivity is not controversial either. Growth hormone antagonizes insulin action through lipolysis and downstream signaling, and chronic hyperinsulinemia promotes receptor downregulation. That part of the physiology is solid.
The specific dose range presented is pure practitioner anecdote. No clinical study has ever examined supraphysiological basal insulin in bodybuilders, so every number in that section is one coach's client pool, nothing more. The claim that hypo risk at any single moment is no greater than with fast acting insulin is a statement about rate of decline, and it conveniently ignores that a prolonged action profile extends the at-risk window across most of a day. A slower drop that lasts eighteen hours is not obviously safer than a faster drop you can counter with carbs in a known timeframe. Severity of hypoglycemia is a function of depth and duration, and long acting analogues extend duration by design. The IGF-1 elevation rationale is likewise extrapolated from mechanistic plausibility, not measured outcomes. Something can raise IGF-1 and still not produce a gram of contractile tissue. The half of the article nobody should skip is the part where the author himself admits he cannot in good conscience recommend daily use. That is the most honest sentence in the piece and it is buried at the end.
The pharmacology comparison the thread is missing. Rapid analogues were engineered to mimic mealtime insulin spikes, acting within minutes and clearing in a few hours, so the hypoglycemia window is short and predictable. Basal analogues were engineered to do the opposite, releasing steadily with minimal peak, which is ideal for stable clinical replacement and uniquely unforgiving for anyone who misjudges carbohydrate intake, trains at the wrong time, or gets sick. Neither profile was designed for supraphysiological use in healthy people. That context matters, because every argument in the article treats a diabetes therapy as if it were simply another ergogenic tool.
On safety, since the thread mostly skips it. Severe hypoglycemia in this context is not a bad feeling, it is a medical event. Sweating, tremor, hunger and confusion are the early autonomic warnings. Once cognition degrades, the ability to self-treat disappears, and that is precisely the danger with a flat, long acting profile, because the window where you can still fix the problem can pass while the drug keeps working for hours afterward. Nighttime is the worst case. Sleeping through the early warnings is how people die from insulin. Anyone using or considering basal insulin needs to understand the emergency picture, glucagon and medical care, not a protein shake by the bed.
The veteran voices in this thread saying most people have no business touching insulin are the ones worth listening to. This is the one compound in the entire toolkit where the margin between effective and fatal is measured in error, not milligrams.
